Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesIn8bio Inc

In8bio Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.88 USD 0.01 ( 0.95%)
Last update at 2026-11-12T15:31:00Z
VOLUME
2224
Market Cap
10.35M

Momentum Score

…

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.88
Low
0.88
High
52 Week Price Range
0.88
Low
2.73
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

In8bio Inc is a clinical-stage biotechnology company focused on developing cell- and gene-based immunotherapies, primarily for oncology. Its long-term growth drivers include positive clinical trial data, regulatory approvals, and strategic partnerships or licensing that could expand the pipeline and commercialization opportunities, which may benefit investors seeking exposure to early-stage therapeutics.

The company faces material risks from clinical trial failures, regulatory setbacks, limited operating history and revenue, and likely need for additional financing that could dilute shareholders.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.87
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.10
ROE
-111.11%
Net Debt
-24.31M
ROCE
-66.76%
Diluted EPS TTM
-1.28

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -19.44M -30.44M -30.01M -28.52M -14.65M
Net income -19.44M -30.44M -30.01M -27.42M -14.65M
Selling general administrative 9.65M 12.64M 13.51M 14.46M 7.31M
Selling and marketing expenses - - 2.50M - -
Gross profit -2.50M -2.65M -2.50M - -
Reconciled depreciation 2.50M 2.65M 2.50M 1.10M 0.79M
Ebit -19.44M -29.60M -30.01M -29.62M -14.65M
Ebitda -16.94M -26.94M -27.51M -28.52M -13.87M
Depreciation and amortization 2.50M 2.65M 2.50M 1.10M 0.79M
Operating income -19.86M -30.44M -30.34M -28.52M -14.65M
Other operating expenses 19.86M 30.44M 30.34M 28.52M 14.65M
Interest expense - - - 1.10M 0.79M
Interest income 0.42M 0.23M 0.00M - -
Net interest income 0.42M 0.23M 0.00M - -
Income tax expense - - -32.84M -1.10M -0.79M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 17.36M 30.44M 27.84M 28.52M 14.65M
Cost of revenue 2.50M 2.65M 2.50M - -
Total other income expense net 0.42M -0.84M 0.33M - -
Net income from continuing ops -19.44M -30.44M -30.01M -28.52M -14.65M
Net income applicable to common shares - - - - -14.65M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 32.28M 20.94M 33.71M 33.04M 42.22M
Intangible assets - - - 0.13M -
Other current assets 0.79M 1.46M 3.34M 4.05M 1.96M
Total liab 4.72M 6.47M 8.77M 10.31M 4.04M
Total stockholder equity 27.56M 14.48M 24.94M 22.73M 38.18M
Other current liab 1.63M 1.05M 2.96M 2.34M 1.24M
Common stock 0.01M 0.01M 0.00M 0.00M 0.00M
Capital stock 0.01M 0.01M 0.00M 0.00M 0.00M
Retained earnings -141.10M -121.66M -91.22M -61.21M -32.69M
Other assets - - - - 0.41M
Cash 27.09M 11.12M 21.28M 18.18M 37.02M
Total current liabilities 3.16M 3.08M 5.39M 5.82M 2.26M
Net debt -24.31M -6.09M -16.39M -12.31M -34.61M
Short term debt 1.22M 1.65M 1.51M 1.39M 0.63M
Short long term debt total 2.78M 5.03M 4.89M 5.87M 2.41M
Other stockholder equity 168.64M 136.13M 116.15M 83.94M 70.87M
Property plant equipment - - - - 2.83M
Total current assets 27.88M 12.58M 24.62M 22.23M 38.98M
Net tangible assets - - - - 38.18M
Accounts payable 0.31M 0.39M 0.92M 2.09M 0.40M
Accumulated other comprehensive income - - - - -42.22M
Non currrent assets other 0.15M 0.28M 0.26M 0.38M 0.41M
Non current assets total 4.40M 8.37M 9.08M 10.80M 3.24M
Capital lease obligations 2.78M 5.03M 4.89M 5.87M 2.41M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.19M -0.60M -3.71M -0.31M
Change to liabilities - - - - -0.32M
Total cashflows from investing activities - -0.19M -0.60M - -0.31M
Net borrowings -0.69M -0.79M -0.80M - -0.71M
Total cash from financing activities 28.64M 14.18M 27.04M 8.99M 32.95M
Change to operating activities - - - - -1.52M
Net income -19.44M -30.44M -30.01M -28.52M -14.65M
Change in cash 15.93M -10.15M 3.10M -18.84M 19.14M
Begin period cash flow 11.39M 21.54M 18.18M 37.27M 18.14M
End period cash flow 27.31M 11.39M 21.28M 18.43M 37.27M
Total cash from operating activities -12.71M -24.15M -23.34M -24.12M -13.51M
Issuance of capital stock 27.07M 9.94M 24.56M 9.54M 36.33M
Depreciation 1.77M 2.65M 2.50M 1.10M 0.79M
Other cashflows from investing activities - -0.08M - - -
Other cashflows from financing activities 28.64M 5.04M 3.28M 0.06M -2.66M
Change to netincome - - - - 2.19M
Capital expenditures 0.00M 0.10M 0.60M 3.71M 0.31M
Change in working capital 1.04M -1.41M -0.20M -0.17M -1.84M
Stock based compensation 3.19M 5.00M 4.37M 3.47M 2.19M
Other non cash items 0.73M 0.04M 4.37M - 2.98M
Free cash flow -12.71M -24.25M -23.94M -27.83M -13.82M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
INAB
In8bio Inc		 0.01
0.95%		 0.88 - - - 0.58 -1.15
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

In8bio Inc

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

350 5th Avenue, New York, NY, United States, 10118

646 600 6438

https://in8bio.com

18

Name Title Year Born
Mr. Tai-Wei Ho Co-Founder, Pres, CEO & Director 1976
Dr. Lawrence S. Lamb Ph.D. Exec. VP, Co-Founder & Chief Scientific Officer 1954
Mr. Patrick McCall CPA CFO & Sec. 1983
Dr. Kate Rochlin Ph.D. Chief Operating Officer 1981
Dr. Trishna Goswami M.D. Chief Medical Officer NA
Dr. Kenneth R. LaMontagne Ph.D. Sr. VP of Bus. Devel. NA
Mr. Tai-Wei Ho Co-Founder, President, CEO & Director 1977
Dr. Trishna Goswami M.D. Chief Medical Officer 1978
Dr. Lawrence S. Lamb Ph.D. Executive VP, Co-Founder & Chief Scientific Officer 1954
Mr. Patrick McCall CPA CFO & Secretary 1983

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…